Browsing by Author "Kaur, Jasleen"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item Opportunities and challenges in application of artificial intelligence in pharmacology(Springer Science and Business Media Deutschland GmbH, 2023-01-09T00:00:00) Kumar, Mandeep; Nguyen, T. P. Nhung; Kaur, Jasleen; Singh, Thakur Gurjeet; Soni, Divya; Singh, Randhir; Kumar, PuneetArtificial intelligence (AI) is a machine science that can mimic human behaviour like intelligent analysis of data. AI functions with specialized algorithms and integrates with deep and machine learning. Living in the digital world can generate a huge amount of medical data every day. Therefore, we need an automated and reliable evaluation tool that can make decisions more accurately and faster. Machine learning has the potential to learn, understand and analyse the data used in healthcare systems. In the last few years, AI is known to be employed in various fields in pharmaceutical science especially in pharmacological research. It helps in the analysis of preclinical (laboratory animals) and clinical (in human) trial data. AI also plays important role in various processes such as drug discovery/manufacturing, diagnosis of big data for disease identification, personalized treatment, clinical trial research, radiotherapy, surgical robotics, smart electronic health records, and epidemic outbreak prediction. Moreover, AI has been used in the evaluation of biomarkers and diseases. In this review, we explain various models and general processes of machine learning and their role in pharmacological science. Therefore, AI with deep learning and machine learning could be relevant in pharmacological research. � 2023, The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.Item Preparation, development and characterization of Leucaena leucocephala galactomannan (LLG) conjugated sinapic acid: A potential colon targeted prodrug(Elsevier B.V., 2021-02-22T00:00:00) Kaur, Jasleen; Mehta, Vikrant; Kaur, GurpreetSinapic acid (SA), a widely prevalent hydroxycinnamic acid, possess numerous biological activities owing to its antioxidant property. The present study was aimed to prepare colon targeted polysaccharidic/polymeric ester prodrug of SA (a microbially triggered system) using Leucaena leucocephala galactomannan (LLG) as a polysaccharidic carrier. The polymeric conjugates of SA-LLG were found to exhibit an increase in % yield and DS with increase in amount of SA and volume of thionyl chloride. The degree of depolymerization of SA-LLG prodrug batches were evaluated using optimized concentration of galactomannase. The SA-LLG prodrug was characterized employing UV and FTIR spectroscopy, 1H NMR and XRD. In vitro release study of the optimized prodrug batch (SL10) suggested stable nature of SA-LLG conjugate under acidic (pH 1.2) and alkaline conditions (pH 6.8). The treatment of prodrug with galactomannase (15 mg/mL) followed by esterase (10 U/mL) enzyme released approximately 81% of SA after 24 h. The cell viability results revealed that free SA and SA-LLG were found to have similar antiproliferative potential against human colon cancer cell lines (HCT-116 cells). Our investigation revealed that polysaccharidic prodrug, SA-LLG, has the potential for colon targeting of SA and thus can be employed for the treatment of Inflammatory Bowel Diseases (IBDs). � 2021 Elsevier B.V.